Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767)
11/2000
11/23/2000WO2000070047A2 Full-length molecules expressed in human tissues
11/23/2000WO2000070046A2 Secreted polypeptides and corresponding polynucleotides
11/23/2000WO2000070042A1 143 human secreted proteins
11/23/2000WO2000070028A1 Sphingosine kinase enzyme
11/23/2000WO2000070025A1 Methods of using rnase p reaction mechanisms of action
11/23/2000WO2000069848A1 Compounds having cytokine inhibitory activity
11/23/2000WO2000069847A1 Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
11/23/2000WO2000069839A1 Hydroxamic and carboxylic acid derivatives
11/23/2000WO2000069838A1 Ion channel modulating agents
11/23/2000WO2000069832A1 Substituted polycyclic aryl and heteroaryl pyrymidinones useful as anticoagulants
11/23/2000WO2000069831A1 Spiroimidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them
11/23/2000WO2000069827A1 Hydroxamic and carboxylic acid derivatives
11/23/2000WO2000069824A1 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/23/2000WO2000069823A1 Ion channel modulating agents
11/23/2000WO2000069822A1 Hydroxamic and carboxylic acid derivatives
11/23/2000WO2000069820A1 Cyclic amine derivatives and their uses
11/23/2000WO2000069818A1 MORPHOLINO-N-ETHYL ESTER DERIVATIVE OF AN INDOLE sPLA2 INHIBITOR
11/23/2000WO2000069472A2 Enzyme-activated anti-tumor prodrug compounds
11/23/2000WO2000069468A1 Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
11/23/2000WO2000069462A1 Human monoclonal antibody
11/23/2000WO2000069426A2 Combination of nicotinic acid or nicotinamide with riboflavin for the treatment of pruritus, itching and inflammation disorders
11/23/2000WO2000069412A1 Method of treating angina and/or anginal equivalents, and pharmaceutical compositions and kit related thereto
11/23/2000WO2000069255A1 Anti-inflammatory therapy for inflammatory mediated infection
11/23/2000WO2000043371A3 Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
11/23/2000WO2000043354A3 Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4
11/23/2000WO2000037502A3 Vascular endothelial cell growth factor antagonists and uses thereof
11/23/2000WO2000034295A3 Acylated benzylmaltosides as inhibitors of smooth muscle cell proliferation
11/23/2000WO2000031100A3 Benzylmaltosides as inhibitors of smooth muscle cell proliferation
11/23/2000WO2000030681A9 Antagonists of the alpha e beta 7 integrin as therapeutic agents for inflammatory diseases
11/23/2000WO2000027423A3 Methods and compositions for treating common cold symptoms
11/23/2000WO2000004863A3 Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
11/23/2000DE19922462A1 New phenylureidobenzyl-substituted spiro-imidazolidinedione derivatives, are inhibitors of leukocyte adhesion or migration or VLA-4 receptors, useful e.g. for treating inflammatory or allergic disease
11/23/2000CA2374559A1 Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
11/23/2000CA2374053A1 Secreted polypeptides and corresponding polynucleotides
11/23/2000CA2373681A1 Pharmaceutical compositions for treating angina and/or anginal equivalents, and kit relating thereto
11/23/2000CA2373614A1 Substituted polycyclic aryl and heteroaryl pyrymidinones useful as anticoagulants
11/23/2000CA2373607A1 Cyclic amine derivatives and their uses
11/23/2000CA2373532A1 Morpholino-n-ethyl ester derivative of an indole spla2 inhibitor
11/23/2000CA2373191A1 Full-length molecules expressed in human tissues
11/23/2000CA2372926A1 143 human secreted proteins
11/23/2000CA2372541A1 Sphingosine kinase enzyme
11/23/2000CA2372494A1 Compounds having cytokine inhibitory activity
11/23/2000CA2372426A1 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/23/2000CA2370245A1 Enzyme-activated anti-tumor prodrug compounds
11/23/2000CA2368593A1 Anti-inflammatory therapy for inflammatory mediated infection
11/22/2000EP1054017A1 Salts of thrombin inhibitors
11/22/2000EP1053343A2 Targeting of genetic vaccine vectors
11/22/2000EP1053312A2 Optimization of immunomodulatory properties of genetic vaccines
11/22/2000EP1053251A1 The aiolos gene
11/22/2000EP1053233A1 Hydroxamic and carboxylic acid derivatives
11/22/2000EP1053009A2 Use of heregulin as an epithelial cell growth factor
11/22/2000EP1052986A1 Anti-inflammatory agents
11/22/2000CN1274288A Peptide-containing & alpha; -ketoamide cysteine and serine protease inhibitors
11/22/2000CN1274283A Quinoline-containing & Alpha;-ketoamide cysteine and serine protease inhibitors
11/21/2000US6150557 Compounds
11/21/2000US6150418 Propellant-free concentrate suitable for storage containing given concentration of formoterol, or salt or addition products thereof as active substance in a solvent or suspension agent; use in inhalation therapy
11/21/2000US6150415 Epoxide hydrolase complexes and methods therewith
11/21/2000US6150378 Peptidyl-containing α-ketoamide cysteine and serine protease inhibitors
11/21/2000US6150373 Bicyclic nitrogen heterocycles
11/21/2000US6150370 1,3-dinitrocyclic compound treats numerous diseases caused by undesired metalloprotease activity, such as tumor metastasis, osteoarthritis, rheumatoid arthritis, skin inflammation, ulcerations, and periodontitis
11/21/2000US6150348 Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
11/21/2000US6150340 RNA-dependent amidotransferase from Staphylococcus aureus
11/21/2000US6150325 Bicyclic tachykinins antagonists, preparation thereof and their use in pharmaceutical compositions
11/21/2000US6150132 Vector coding polypeptides for the diagnosis and treatment of allergies and atherosclerosis; for the prevention of graft ejection and injuries to stem cell caused by anticarcinogenic agents
11/21/2000US6150101 Methods of identifying a composition that alters connective tissue growth factor expression
11/21/2000US6149892 Metered dose inhaler for beclomethasone dipropionate
11/16/2000WO2000068380A2 Extracellular matrix and adhesion-associated proteins
11/16/2000WO2000068255A2 Tetrapeptide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application
11/16/2000WO2000068246A1 Steroid compounds with a c17-alkyl side chain and an aromatic a-ring for use in therapy
11/16/2000WO2000068243A1 Methods using mechanisms of action of aroa
11/16/2000WO2000068231A1 Purine derivative dihydrate, drugs containing the same as the active ingredient and intermediate in the production thereof
11/16/2000WO2000068230A1 9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as pde7 inhibitors
11/16/2000WO2000068224A1 Substituted benzolactam compounds
11/16/2000WO2000068223A1 Ureas and their use as cell adhesion modulators
11/16/2000WO2000068215A1 Diphenyl-1,2,3-thiadiazol-3-oxides, compositions and methods of use
11/16/2000WO2000068213A1 Substituted bicyclic compounds
11/16/2000WO2000068198A2 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/16/2000WO2000068195A2 Substituted pyrrolidines as cell adhesion inhibitors
11/16/2000WO2000068188A1 Propanoic acid derivatives that inhibit the binding of integrins to their receptors
11/16/2000WO2000067801A2 Prodrugs of chemotherapeutic agents with oxaalkanoic acids
11/16/2000WO2000067796A1 Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
11/16/2000WO2000067791A1 Ccr4 antagonists in sepsis
11/16/2000WO2000067746A1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
11/16/2000WO2000038665A3 Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
11/16/2000WO2000037639A3 Lymphocytic membrane proteins
11/16/2000WO2000037025A3 Antibodies to truncated vegf-d and uses thereof
11/16/2000WO2000034331A3 Analogues of glp-1
11/16/2000WO2000027377A3 Phosphinate peptide analogs for the treatment of fibrotic disorders
11/16/2000WO2000026224A3 Novel macrolide antibiotics
11/16/2000DE19921693A1 Pharmaceutical composition for treating respiratory disorders, e.g. asthma, comprises combination of anticholinergic and beta-mimetic agents having synergistic bronchospasmolytic activity and reduced side-effects
11/16/2000DE19920247A1 Arzneimittel mit einem Gehalt an Verbindungen mit einem Stickstoff-Sauerstoff-Heterocyclus als Wirkstoff und ihre Verwendung Medicaments with an amount of compounds having a nitrogen-oxygen heterocycle as active ingredient and their use
11/16/2000CA2373443A1 Steroid compounds with a c17-alkyl side chain and an aromatic a-ring for use in therapy
11/16/2000CA2373079A1 Substituted benzolactam compounds
11/16/2000CA2373015A1 Purine derivative dihydrate, drugs containing the same as the active ingredient and intermediate in the production thereof
11/16/2000CA2372815A1 Extracellular matrix and adhesion-associated proteins
11/16/2000CA2369333A1 Diphenyl-1,2,3-thiadiazol-3-oxides, compositions and methods of use
11/16/2000CA2369323A1 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/16/2000CA2368831A1 Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids
11/15/2000EP1052254A1 Nitrogenous heterocyclic derivatives and medicine thereof
11/15/2000EP1051489A2 Compounds for therapy and diagnosis of lung cancer and methods for their use